Answer
Women taking vismodegib (Erivedge) must avoid breastfeeding during treatment and for 24 months after the final dose because of its potential to cause serious developmental defects.
Sources for this answer
- Erivedge 150 mg hard capsulesRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 20Document updated
Sources checked